West Pharmaceutical Services (WST) Stock Price, News & Analysis

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" WST shares.
View WST analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month target prices for West Pharmaceutical Services' stock. Their WST share price targets range from $375.00 to $536.00. On average, they expect the company's stock price to reach $435.20 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $352.12 on January 1st, 2024. Since then, WST shares have increased by 7.6% and is now trading at $378.81.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our WST earnings forecast.

West Pharmaceutical Services will be holding an earnings conference call on Thursday, April 25th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

West Pharmaceutical Services, Inc. (NYSE:WST) announced its earnings results on Thursday, February, 15th. The medical instruments supplier reported $1.83 EPS for the quarter, beating the consensus estimate of $1.78 by $0.05. The medical instruments supplier had revenue of $732 million for the quarter, compared to analysts' expectations of $740.43 million. West Pharmaceutical Services had a trailing twelve-month return on equity of 21.60% and a net margin of 20.12%. The firm's quarterly revenue was up 3.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.77 EPS.
Read the conference call transcript.

West Pharmaceutical Services declared a quarterly dividend on Tuesday, February 20th. Stockholders of record on Wednesday, April 24th will be paid a dividend of $0.20 per share on Wednesday, May 1st. This represents a $0.80 annualized dividend and a dividend yield of 0.21%. The ex-dividend date of this dividend is Tuesday, April 23rd.
Read our dividend analysis for WST.

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.21%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.15%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 8.77% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

ETFs with the largest weight of West Pharmaceutical Services (NYSE:WST) stock in their portfolio include Subversive Mental Health ETF (SANE), BTD Capital Fund (DIP), VictoryShares THB Mid Cap ESG ETF (MDCP), Formidable Fortress ETF (KONG), Nuveen ESG Mid-Cap Growth ETF (NUMG), Goldman Sachs Future Health Care Equity ETF (GDOC), BlackRock Future Health ETF (BMED) and BlackRock Future Innovators ETF (BFTR).

West Pharmaceutical Services issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 7.500-7.750 for the period, compared to the consensus earnings per share estimate of 8.760. The company issued revenue guidance of $3.0 billion-$3.0 billion, compared to the consensus revenue estimate of $3.2 billion.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services' stock is owned by a variety of institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.45%), Rockland Trust Co. (0.07%), Annex Advisory Services LLC (0.03%), Apella Capital LLC (0.02%), Portman Square Capital LLP (0.00%) and Czech National Bank (0.02%). Insiders that own company stock include Annette F Favorite, Bernard Birkett, Chad Winters, Charles Witherspoon, Cindy Reiss-Clark, Eric Mark Green, Quintin J Lai, Silji Abraham and Thomas W Hofmann.
View institutional ownership trends.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.